Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -9.62 is 136% below its 3-year average of -4.07, near the low end of its 3-year range (-9.62–-0.97).
57.70% below its 12-month average of -6.10.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -1.77.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 7 comparable quarters.
EARNINGS PER SHARE (EPS)
-9.62
EARNINGS PER SHARE (EPS) AVG TTM
-6.10
EARNINGS PER SHARE (EPS) AVG 3Y
-4.07
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-57.70%
CURRENT VS 3Y AVG
-136.36%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Zenas BioPharma, Inc.
Market Cap
$1.70B
Earnings Per Share (EPS)
-9.62
TTM Avg
-6.10
3Y Avg
-4.07
5Y Avg
N/A
Market Cap
$1.71B
Earnings Per Share (EPS)
-2.74
TTM Avg
-3.74
3Y Avg
-3.13
5Y Avg
-1.84
Market Cap
$1.71B
Earnings Per Share (EPS)
-1.09
TTM Avg
-1.14
3Y Avg
-1.75
5Y Avg
-1.62
Market Cap
$1.73B
Earnings Per Share (EPS)
-3.36
TTM Avg
-4.53
3Y Avg
-5.16
5Y Avg
-4.47
Market Cap
$1.74B
Earnings Per Share (EPS)
0.19
TTM Avg
-0.34
3Y Avg
-0.57
5Y Avg
-0.59
Market Cap
$1.74B
Earnings Per Share (EPS)
-0.10
TTM Avg
-0.18
3Y Avg
-0.38
5Y Avg
-0.87
Market Cap
$1.74B
Earnings Per Share (EPS)
-0.80
TTM Avg
-0.89
3Y Avg
-1.03
5Y Avg
-0.96
Market Cap
$1.74B
Earnings Per Share (EPS)
-1.30
TTM Avg
-1.39
3Y Avg
-1.40
5Y Avg
-0.99
Market Cap
$1.75B
Earnings Per Share (EPS)
-0.69
TTM Avg
-0.97
3Y Avg
-0.66
5Y Avg
-1.16
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Zenas BioPharma, Inc. (ZBIO) | $1.70B | -9.62 | -6.10 | -4.07 | N/A |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $1.71B | -2.74 | -3.74 | -3.13 | -1.84 |
| Personalis, Inc. (PSNL)vs › | $1.71B | -1.09 | -1.14 | -1.75 | -1.62 |
| Intellia Therapeutics, Inc. (NTLA)vs › | $1.73B | -3.36 | -4.53 | -5.16 | -4.47 |
| Alignment Healthcare, Inc. (ALHC)vs › | $1.74B | 0.19 | -0.34 | -0.57 | -0.59 |
| Xeris Biopharma Holdings, Inc. (XERS)vs › | $1.74B | -0.10 | -0.18 | -0.38 | -0.87 |
| Absci Corporation (ABSI)vs › | $1.74B | -0.80 | -0.89 | -1.03 | -0.96 |
| Novocure Ltd (NVCR)vs › | $1.74B | -1.30 | -1.39 | -1.40 | -0.99 |
| Surgery Partners, Inc. (SGRY)vs › | $1.75B | -0.69 | -0.97 | -0.66 | -1.16 |
| Generate Biomedicines, Inc. (GENB)vs › | $1.77B | N/A | -3.33 | -3.33 | -3.33 |
Trailing EPS (TTM)
$-9.62
Forward EPS (Est.)
$-5.63
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -8.44 |
| 2024-12-31 | -3.76 |
| 2023-12-31 | -0.97 |
| 2022-12-31 | -3.11 |
